Summary
"Pharma73 SA is a Portuguese start-up dedicated to the development, production and commercialization of a new generation
of High Functionality Excipients (HFEs). Excipients are inactive ingredients used together with active ingredients to formulate
drugs into finished dosage forms. Ranging from 15% to 95% of the total weight of a given drug, excipients are extremely
important in terms of procurement, logistics, quality control and final batch release. Pharma73’s technology is based on the
production of natural polymers, such as the Chitin Glucan Complex HPE1, obtained from fermentation processes whose
unique properties enable their application in a multiplicity of pharmaceutical drugs for oral solid-dosage forms. Adding HPE1
to the final drug formulation will result in better yields and operational savings for the manufacturing industry, thanks to
significant functional - physical and chemical properties of the new excipient. Pharma73’s ambition is to introduce a new raw
material into the excipient markets, and bring the industry to a new level that better responds to efficiency and sustainability
requirements of the drug manufacturing process. Furthermore the innovation related to the adoption of HPE1 will preserve
the EU’s competitive advantage over drug manufacturing procedures, creating more job opportunities, and the long-term
viability of a European-based pharmaceutical industry. Therefore the commercialization of a novel class of excipients like
HPE1 aligns with the EU strategy “Europe 2020 – for a healthier EU”: 1) “Innovation can help make the healthcare sector
more sustainable” 2) “the healthcare sector has an important role to play in improving skills and creating jobs as it employs 1
in 10 of the most qualified workers in the EU"".
The SME instrument will allow Pharma 73 to complete their go-to-market strategy, by demonstrating HPE1 potential for
specific drug formulation uses."
of High Functionality Excipients (HFEs). Excipients are inactive ingredients used together with active ingredients to formulate
drugs into finished dosage forms. Ranging from 15% to 95% of the total weight of a given drug, excipients are extremely
important in terms of procurement, logistics, quality control and final batch release. Pharma73’s technology is based on the
production of natural polymers, such as the Chitin Glucan Complex HPE1, obtained from fermentation processes whose
unique properties enable their application in a multiplicity of pharmaceutical drugs for oral solid-dosage forms. Adding HPE1
to the final drug formulation will result in better yields and operational savings for the manufacturing industry, thanks to
significant functional - physical and chemical properties of the new excipient. Pharma73’s ambition is to introduce a new raw
material into the excipient markets, and bring the industry to a new level that better responds to efficiency and sustainability
requirements of the drug manufacturing process. Furthermore the innovation related to the adoption of HPE1 will preserve
the EU’s competitive advantage over drug manufacturing procedures, creating more job opportunities, and the long-term
viability of a European-based pharmaceutical industry. Therefore the commercialization of a novel class of excipients like
HPE1 aligns with the EU strategy “Europe 2020 – for a healthier EU”: 1) “Innovation can help make the healthcare sector
more sustainable” 2) “the healthcare sector has an important role to play in improving skills and creating jobs as it employs 1
in 10 of the most qualified workers in the EU"".
The SME instrument will allow Pharma 73 to complete their go-to-market strategy, by demonstrating HPE1 potential for
specific drug formulation uses."
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/744285 |
| Start date: | 01-12-2016 |
| End date: | 30-04-2017 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
"Pharma73 SA is a Portuguese start-up dedicated to the development, production and commercialization of a new generationof High Functionality Excipients (HFEs). Excipients are inactive ingredients used together with active ingredients to formulate
drugs into finished dosage forms. Ranging from 15% to 95% of the total weight of a given drug, excipients are extremely
important in terms of procurement, logistics, quality control and final batch release. Pharma73’s technology is based on the
production of natural polymers, such as the Chitin Glucan Complex HPE1, obtained from fermentation processes whose
unique properties enable their application in a multiplicity of pharmaceutical drugs for oral solid-dosage forms. Adding HPE1
to the final drug formulation will result in better yields and operational savings for the manufacturing industry, thanks to
significant functional - physical and chemical properties of the new excipient. Pharma73’s ambition is to introduce a new raw
material into the excipient markets, and bring the industry to a new level that better responds to efficiency and sustainability
requirements of the drug manufacturing process. Furthermore the innovation related to the adoption of HPE1 will preserve
the EU’s competitive advantage over drug manufacturing procedures, creating more job opportunities, and the long-term
viability of a European-based pharmaceutical industry. Therefore the commercialization of a novel class of excipients like
HPE1 aligns with the EU strategy “Europe 2020 – for a healthier EU”: 1) “Innovation can help make the healthcare sector
more sustainable” 2) “the healthcare sector has an important role to play in improving skills and creating jobs as it employs 1
in 10 of the most qualified workers in the EU"".
The SME instrument will allow Pharma 73 to complete their go-to-market strategy, by demonstrating HPE1 potential for
specific drug formulation uses."
Status
CLOSEDCall topic
SMEInst-05-2016-2017Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
